Skip to main content

Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response

  • The Commentary to this article has been published in Stem Cell Research & Therapy 2020 11:173

Abstract

We would like to thank for the interest for the article and comments in the response. We believe that cell therapy may offer a treatment for severe voice problems in patients with vocal fold scarring and MSC treatment is a valuable alternative.

Commentary

The main aim of the study was safety aspects of the MSC treatment, and we found no side effects or complications after the treatment. All patients were followed for 1 year and subsequently for another 3–5 extra years. The 3 patients which were previously treated for laryngeal cancer (all at least 15 years before MSC treatment) have so far been followed between 5 and 7 years. We therefore think that the treatment is safe. Human BM-derived MSCs have never been reported to cause tumors in animals or humans. There are reports of in vitro transformation of human MSC, but these results were later shown to be the result of contamination by transformed cell lines in the cell lab [1,2,3]. Autologous (and allogeneic) MSCs have been administered, as local injection or intravenous infusion, to > 10,000 patients worldwide, without reported side effects. Long-term engraftment is low, and we avoid the risk for alloreactive reactions by using autologous cells. The harvest of the bone marrow from the iliac crest may result in local pain, but none of our patients complained about this. However, other sources of MSC may well be used as pointed out in the response. It is important to characterize the cells used in any clinical trials according to international guidelines.

The procedure with scar resection before MSC injection is discussed in the response. We chose this procedure because all our animal studies preceding the clinical human trial showed positive results regarding healing, inflammatory response, and functional result, both in “acute” damage model and after resecting present scar tissue [4,5,6,7,8]. It is true that scar resection alone may give some positive effects regarding vocal function in selected cases. There is however a clear risk for deteriorated voice and/or vocal fold function, and we were not willing to risk this, especially since this was the first study in humans. Also our previous animal studies showed significantly deteriorated viscoelastic properties and more scar formation, both in the acute damage model and after resection of present scar without the MSC treatment [4,5,6]. Another option is of course to have a control group where MSCs are injected without scar resection. Our results were less positive for patients with larger scar defects. We agree with the viewpoints in the response that these patients probably should be treated with a combination with MSC or other cell therapy (without scar resection) and a suitable scaffold which works well with the cells.

For the validated Swedish version of VHI30, a number of 13 points difference for total score is considered clinical relevant [9]. We would like to point out that only 3 patients were treated bilateral in our study although 9 had bilateral vocal fold damage. This may affect the results both for VHI and vocal fold parameters.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available [due to data are kept protected following the routines of the Institution at Karolinska Institutet], but are available from the corresponding author on reasonable request.

References

  1. 1.

    Rosland GV, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009;69(13):5331–9.

    CAS  Article  Google Scholar 

  2. 2.

    Torsvik A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res. 2010;70(15):6393–6.

    CAS  Article  Google Scholar 

  3. 3.

    Torsvik A, Rosland GV, Bjerkvig R. Comment to: “Spontaneous transformation of adult mesenchymal stem cells from cynomolgus macaques in vitro” by Z. Ren et al. Exp. Cell Res. 317 (2011) 2950-2957: spontaneous transformation of mesenchymal stem cells in culture: facts or fiction? Exp Cell Res. 2012;318(5):441–3.

    CAS  Article  Google Scholar 

  4. 4.

    Hertegard S, et al. Viscoelastic and histologic properties in scarred rabbit vocal folds after mesenchymal stem cell injection. Laryngoscope. 2006;116(7):1248–54.

    CAS  Article  Google Scholar 

  5. 5.

    Svensson B, et al. Injection of human mesenchymal stem cells improves healing of scarred vocal folds: analysis using a xenograft model. Laryngoscope. 2010;120(7):1370–5.

    Article  Google Scholar 

  6. 6.

    Svensson B, et al. Injection of human mesenchymal stem cells improves healing of vocal folds after scar excision--a xenograft analysis. Laryngoscope. 2011;121(10):2185–90.

    Article  Google Scholar 

  7. 7.

    Nagubothu SR, Sugars RV, Tudzarovski N, Törnqvist Andrén A, Bottai M, Davies LC, Hertegård S, Le Blanc K. Mesenchymal stromal cells modulate tissue repair responses within the injured vocal fold. Laryngoscope. 2019. https://doi.org/10.1002/lary.27885 [Epub ahead of print].

  8. 8.

    Hertegård S, Nagubothu SR, Malmström E, Ström C, Tolf A, Davies LC, Le Blanc K. Hyaluronan hydrogels offer a safe and efficient means for the local delivery of mesenchymal stromal cells to the injured vocal fold. Stem Cells Dev. 2019. https://doi.org/10.1089/scd.2019.0102 [Epub ahead of print].

  9. 9.

    Ohlsson AC, Dotevall H. Voice handicap index in Swedish. Log Phon Voc. 2009;34:60–6.

    Article  Google Scholar 

Download references

Funding

The Swedish Research Council (K2011-X-20742-04-6), Stockholm County Council (ALF Medicin, 20110152), Swedish Foundation for Strategic Research, IKE-2014-00354), Laryngfonden (50/14), Karolinska Institutet.

Author information

Affiliations

Authors

Contributions

SH and KLB contributed equally to the commentary text. Both authors read and approved the manuscript.

Corresponding author

Correspondence to Stellan Hertegård.

Ethics declarations

Ethics approval and consent to participate

Ethical permissions (DNR 2010/1650 and DNR 2014/51432) were received from the Stockholm regional ethical review committee. Patients provided written informed consent before the procedure. The MSC expansion procedure was accredited by the Swedish National Board of Health and Welfare (952/2009, 6.3.3-8874/2011, 6.1.3-9791/2013, 6.1.3-16411/201).

Consent for publication

The patients gave consent for the publication of the data (made unidentifiable).

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hertegård, S., LeBlanc, K. Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response. Stem Cell Res Ther 11, 235 (2020). https://doi.org/10.1186/s13287-020-01748-x

Download citation

Keywords

  • Vocal fold
  • Scarring
  • Hoarseness
  • Mesenchymal stromal cells
  • Fibrosis
  • Immunomodulation
  • Wound healing